Patent ID: 9249163
Filing Date: 2016-02-02
CPC Classification: A61P,C07D

Claim Text:
1. A compound of Formula (I) wherein G is a substituent selected from the group consisting of R (i) hydrogen; (ii) a substituent selected from the group consisting of pyridinyl, 1H-pyrazol-4-yl, 5-pyrimidinyl, 5-hydroxy-1,2,4-oxadiazol-3-yl, 1H-imidazo[4,5-b]pyridin-6-yl, 2-hydroxy-1H-imidazo[4,5-b]pyridin-6-yl, and a ring 1-a to 1-h wherein the pyridinyl and 5-pyrimidinyl rings of group (iii) are optionally substituted with one substituent selected from the group consisting of C and wherein said pyridinyl of group (iii) is optionally further substituted with one or two substituents selected from the group consisting of fluoro, chloro, and hydroxy; wherein said 1H-pyrazol-4-yl of group (iii) is optionally substituted at the 1-position with methoxy-ethyl or carboxy(C (iii) phenyl optionally substituted at the 4-position with one substituent that is C 1-4 alkoxycarbonyl, C 1-4 alkylcarbonylaminosulfonyl, C 1-4 alkylaminosulfonyl, (2-hydroxyethyl)aminosulfonyl, aminosulfonyl, C 1-4 alkylsulfonylaminocarbonyl, carboxy, —O(CH 2 CH 2 O) 2-5 CH 3 , —OCH 2 OCH 3 , carboxy(C 1-4 )alkylaminocarbonyl, 2-carboxypyrrolidin-1-ylcarbonyl, carboxy(C 1-4 )alkylcarbonylamino, C 1-4 alkylsulfonylaminocarbonylamino, carboxy(C 1-4 )alkylamino, bis(2-hydroxyethyl)aminocarbonylamino, (2-hydroxyethyl)aminocarbonylamino, 1,1,1,3,3,3-hexafluoro-2-hydroxy-propan-2-yl, 4-carboxypiperidin-1-yl, piperazin-1-yl, triazolylthio, tetrazolyl, triazolyl, imidazolyl, or oxazolyl; wherein said tetrazolyl, triazolyl, imidazolyl, or oxazolyl substituents are optionally independently substituted with one or two substituents selected from the group consisting of C 1-4 alkyl and hydroxy; and wherein said phenyl ring of group (iii) is optionally independently further substituted with one or two substituents selected from the group consisting of C (iv) phenyl substituted at the 4-position with one substituent that is r-1, r-2, or r-3; wherein said phenyl ring of group (iv) is optionally further substituted with one additional fluoro substituent; (v) phenyl substituted at the 4-position with p-1 or p-2; or (vi) piperidin-4-yl optionally substituted at the 1-position with aminosulfonyl or carboxy(C 1-4 )alkyl; R L is a bivalent linker that is ethyl, E-ethenyl, ethynyl, trans-1,3-cyclobutyl, cis-1,3-cyclobutyl, azetidinyl, —CH Q is quinolin-2-yl, pyridinyl, pyrimidinyl, quinazolin-2-yl, benzimidazol-2-yl, or benzothiazol-2-yl; wherein said Q is optionally independently substituted with one or two substituents selected from the group consisting of C 1-4 alkyl, carboxy-methoxy, C 1-4 alkoxy, and carboxy; or an enantiomer, diastereomer, or pharmaceutically acceptable salt form thereof.